Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy
Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection. We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of...
Gespeichert in:
Veröffentlicht in: | Journal of acquired immune deficiency syndromes (1999) 2017-07, Vol.75 (3), p.364-369 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 369 |
---|---|
container_issue | 3 |
container_start_page | 364 |
container_title | Journal of acquired immune deficiency syndromes (1999) |
container_volume | 75 |
creator | Perkins, Matthew J Bradley, William P Lalani, Tahaniyat Agan, Brian K Whitman, Timothy J Ferguson, Tomas M Okulicz, Jason F Ganesan, Anuradha |
description | Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection.
We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups.
From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs.
While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies. |
doi_str_mv | 10.1097/QAI.0000000000001393 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1886753663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1886753663</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2963-a04ac08212b4a5ca994024ab6bdd2b1c2107d918d02a4f865f31b71a4e0804e53</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhi1ERb_4BwhZ4sIlxd-xuS0raCNV6rYUrpGTTGiqrB3G3kp754dj1IJQ5zJzeN5XIz2EvOHsjDNXf7heNWfsv-HSyRfkiDulqtpa9bLcWuhKcakPyXFK94UxSrlX5FBY6ZTV5oj8-oQTjPQGloj5I90gPPgZQg80jnQTU84IPm8hZLqOIWOcZ0C6uYMQ834B2iR64xHoFOhF871qwgh9hoFuAFMMia7GXPivOS7LFH7QVcgTQql5mNDP9PYO0C_7U3Iw-jnB66d9Qr59-Xy7vqgur86b9eqy6oUzsvJM-Z5ZwUWnvO69c4oJ5TvTDYPoeC84qwfH7cCEV6M1epS8q7lXwCxToOUJef_Yu2D8uYOU2-2UephnHyDuUsutNbWWxsiCvnuG3scdhvJdy51QhhttXaHUI9VjTAlhbBecth73LWftH0ttsdQ-t1Rib5_Kd90Whn-hv1rkb98YjVk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1924616589</pqid></control><display><type>article</type><title>Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy</title><source>Freely Accessible Journals</source><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Journals@Ovid Complete</source><creator>Perkins, Matthew J ; Bradley, William P ; Lalani, Tahaniyat ; Agan, Brian K ; Whitman, Timothy J ; Ferguson, Tomas M ; Okulicz, Jason F ; Ganesan, Anuradha</creator><creatorcontrib>Perkins, Matthew J ; Bradley, William P ; Lalani, Tahaniyat ; Agan, Brian K ; Whitman, Timothy J ; Ferguson, Tomas M ; Okulicz, Jason F ; Ganesan, Anuradha</creatorcontrib><description>Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection.
We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups.
From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs.
While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies.</description><identifier>ISSN: 1525-4135</identifier><identifier>EISSN: 1944-7884</identifier><identifier>DOI: 10.1097/QAI.0000000000001393</identifier><identifier>PMID: 28394856</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins Ovid Technologies</publisher><subject>Adult ; AIDS/HIV ; Anti-HIV Agents - therapeutic use ; Antiretroviral agents ; Antiretroviral drugs ; Antiretroviral therapy ; CD4 antigen ; CD4 Lymphocyte Count ; Chronic infection ; Demographics ; Disease control ; Disease Progression ; Drug Administration Schedule ; Female ; Genotype & phenotype ; HIV ; HIV Infections - drug therapy ; HIV Infections - immunology ; HIV Long-Term Survivors - statistics & numerical data ; Human immunodeficiency virus ; Humans ; Male ; Military Personnel ; Patients ; Prevalence ; Restarting ; Retrospective Studies ; RNA, Viral ; Therapy ; Viral Load ; Viremia ; Viremia - immunology</subject><ispartof>Journal of acquired immune deficiency syndromes (1999), 2017-07, Vol.75 (3), p.364-369</ispartof><rights>Copyright Lippincott Williams & Wilkins Jul 1, 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2963-a04ac08212b4a5ca994024ab6bdd2b1c2107d918d02a4f865f31b71a4e0804e53</citedby><cites>FETCH-LOGICAL-c2963-a04ac08212b4a5ca994024ab6bdd2b1c2107d918d02a4f865f31b71a4e0804e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28394856$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perkins, Matthew J</creatorcontrib><creatorcontrib>Bradley, William P</creatorcontrib><creatorcontrib>Lalani, Tahaniyat</creatorcontrib><creatorcontrib>Agan, Brian K</creatorcontrib><creatorcontrib>Whitman, Timothy J</creatorcontrib><creatorcontrib>Ferguson, Tomas M</creatorcontrib><creatorcontrib>Okulicz, Jason F</creatorcontrib><creatorcontrib>Ganesan, Anuradha</creatorcontrib><title>Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy</title><title>Journal of acquired immune deficiency syndromes (1999)</title><addtitle>J Acquir Immune Defic Syndr</addtitle><description>Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection.
We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups.
From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs.
While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies.</description><subject>Adult</subject><subject>AIDS/HIV</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral drugs</subject><subject>Antiretroviral therapy</subject><subject>CD4 antigen</subject><subject>CD4 Lymphocyte Count</subject><subject>Chronic infection</subject><subject>Demographics</subject><subject>Disease control</subject><subject>Disease Progression</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Genotype & phenotype</subject><subject>HIV</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - immunology</subject><subject>HIV Long-Term Survivors - statistics & numerical data</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Male</subject><subject>Military Personnel</subject><subject>Patients</subject><subject>Prevalence</subject><subject>Restarting</subject><subject>Retrospective Studies</subject><subject>RNA, Viral</subject><subject>Therapy</subject><subject>Viral Load</subject><subject>Viremia</subject><subject>Viremia - immunology</subject><issn>1525-4135</issn><issn>1944-7884</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1v1DAQhi1ERb_4BwhZ4sIlxd-xuS0raCNV6rYUrpGTTGiqrB3G3kp754dj1IJQ5zJzeN5XIz2EvOHsjDNXf7heNWfsv-HSyRfkiDulqtpa9bLcWuhKcakPyXFK94UxSrlX5FBY6ZTV5oj8-oQTjPQGloj5I90gPPgZQg80jnQTU84IPm8hZLqOIWOcZ0C6uYMQ834B2iR64xHoFOhF871qwgh9hoFuAFMMia7GXPivOS7LFH7QVcgTQql5mNDP9PYO0C_7U3Iw-jnB66d9Qr59-Xy7vqgur86b9eqy6oUzsvJM-Z5ZwUWnvO69c4oJ5TvTDYPoeC84qwfH7cCEV6M1epS8q7lXwCxToOUJef_Yu2D8uYOU2-2UephnHyDuUsutNbWWxsiCvnuG3scdhvJdy51QhhttXaHUI9VjTAlhbBecth73LWftH0ttsdQ-t1Rib5_Kd90Whn-hv1rkb98YjVk</recordid><startdate>20170701</startdate><enddate>20170701</enddate><creator>Perkins, Matthew J</creator><creator>Bradley, William P</creator><creator>Lalani, Tahaniyat</creator><creator>Agan, Brian K</creator><creator>Whitman, Timothy J</creator><creator>Ferguson, Tomas M</creator><creator>Okulicz, Jason F</creator><creator>Ganesan, Anuradha</creator><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7T5</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>20170701</creationdate><title>Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy</title><author>Perkins, Matthew J ; Bradley, William P ; Lalani, Tahaniyat ; Agan, Brian K ; Whitman, Timothy J ; Ferguson, Tomas M ; Okulicz, Jason F ; Ganesan, Anuradha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2963-a04ac08212b4a5ca994024ab6bdd2b1c2107d918d02a4f865f31b71a4e0804e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>AIDS/HIV</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral drugs</topic><topic>Antiretroviral therapy</topic><topic>CD4 antigen</topic><topic>CD4 Lymphocyte Count</topic><topic>Chronic infection</topic><topic>Demographics</topic><topic>Disease control</topic><topic>Disease Progression</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Genotype & phenotype</topic><topic>HIV</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - immunology</topic><topic>HIV Long-Term Survivors - statistics & numerical data</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Male</topic><topic>Military Personnel</topic><topic>Patients</topic><topic>Prevalence</topic><topic>Restarting</topic><topic>Retrospective Studies</topic><topic>RNA, Viral</topic><topic>Therapy</topic><topic>Viral Load</topic><topic>Viremia</topic><topic>Viremia - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perkins, Matthew J</creatorcontrib><creatorcontrib>Bradley, William P</creatorcontrib><creatorcontrib>Lalani, Tahaniyat</creatorcontrib><creatorcontrib>Agan, Brian K</creatorcontrib><creatorcontrib>Whitman, Timothy J</creatorcontrib><creatorcontrib>Ferguson, Tomas M</creatorcontrib><creatorcontrib>Okulicz, Jason F</creatorcontrib><creatorcontrib>Ganesan, Anuradha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perkins, Matthew J</au><au>Bradley, William P</au><au>Lalani, Tahaniyat</au><au>Agan, Brian K</au><au>Whitman, Timothy J</au><au>Ferguson, Tomas M</au><au>Okulicz, Jason F</au><au>Ganesan, Anuradha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy</atitle><jtitle>Journal of acquired immune deficiency syndromes (1999)</jtitle><addtitle>J Acquir Immune Defic Syndr</addtitle><date>2017-07-01</date><risdate>2017</risdate><volume>75</volume><issue>3</issue><spage>364</spage><epage>369</epage><pages>364-369</pages><issn>1525-4135</issn><eissn>1944-7884</eissn><abstract>Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection.
We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups.
From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs.
While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins Ovid Technologies</pub><pmid>28394856</pmid><doi>10.1097/QAI.0000000000001393</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1525-4135 |
ispartof | Journal of acquired immune deficiency syndromes (1999), 2017-07, Vol.75 (3), p.364-369 |
issn | 1525-4135 1944-7884 |
language | eng |
recordid | cdi_proquest_miscellaneous_1886753663 |
source | Freely Accessible Journals; MEDLINE; Journals@Ovid LWW Legacy Archive; Journals@Ovid Complete |
subjects | Adult AIDS/HIV Anti-HIV Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Antiretroviral therapy CD4 antigen CD4 Lymphocyte Count Chronic infection Demographics Disease control Disease Progression Drug Administration Schedule Female Genotype & phenotype HIV HIV Infections - drug therapy HIV Infections - immunology HIV Long-Term Survivors - statistics & numerical data Human immunodeficiency virus Humans Male Military Personnel Patients Prevalence Restarting Retrospective Studies RNA, Viral Therapy Viral Load Viremia Viremia - immunology |
title | Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T13%3A17%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Brief%20Report:%20Prevalence%20of%20Posttreatment%20Controller%20Phenotype%20Is%20Rare%20in%20HIV-Infected%20Persons%20After%20Stopping%20Antiretroviral%20Therapy&rft.jtitle=Journal%20of%20acquired%20immune%20deficiency%20syndromes%20(1999)&rft.au=Perkins,%20Matthew%20J&rft.date=2017-07-01&rft.volume=75&rft.issue=3&rft.spage=364&rft.epage=369&rft.pages=364-369&rft.issn=1525-4135&rft.eissn=1944-7884&rft_id=info:doi/10.1097/QAI.0000000000001393&rft_dat=%3Cproquest_cross%3E1886753663%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1924616589&rft_id=info:pmid/28394856&rfr_iscdi=true |